$MESO News
Last published 1w ago
- 1w agoMESOUse Of Ryoncil First Line After Steroids For Pediatric Acute Graft Versus Host Disease Highlighted In Key Opinion Leader WebinarGlobeNewswireNEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, announced that it hosted a key opinion leader webinar
- 1w agoMESOMesoblast Board ChangesGlobeNewswireNEW YORK, Nov. 01, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced rotational changes and retirement of
- 2w agoMESOActivity Report for Quarter Ended September 30, 2026 (Appendix 4C)GlobeNewswireNEW YORK, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today provided its activity report for the first fiscal
- 2mo agoMESOMesoblast Reports Substantial Revenue Growth to US$120MGlobeNewswireRYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment Financial Results and Operational Update for Full Year Ended June 30, 2026 NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited
- 2mo agoMESOMesoblast Financial Results and Corporate Update WebcastGlobeNewswireNEW YORK, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited ((ASX:MSB, NASDAQ:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights
- 2mo agoMESOMesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back PainGlobeNewswireNEW YORK, Aug. 16, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has completed patient treatment
- 3mo agoMESOMesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product LaunchGlobeNewswireExpanding indications for RYONCIL in children and adults with life-threatening inflammatory diseases Achieved target of at least 300 Patients treated in Pivotal Phase 3 trial for Chronic Low Back Pain Activity
- 4mo agoMESOMesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back PainGlobeNewswireNEW YORK, July 13, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has achieved its target of at
- 4mo agoMESOMesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADsGlobeNewswireNEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited ((ASX:MSB, NASDAQ:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received a Biologics License
- 4mo agoMESOMesoblast Draws US$50 Million from Five-Year Non-Dilutive FacilityGlobeNewswireOptimized capital structure, retiring short-term maturing debt Well-funded for commercial operations and growth pipeline NEW YORK, June 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global
- 5mo agoCNXUIARTEOLSBVS+1Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing ItPR NewswireUSA News Group News Commentary — Wall Street's regenerative medicine bench just got one name deeper. On May 21, 2026, Conexeu Sciences Inc. (Nasdaq:...
- 6mo agoMESOMesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 MillionGlobeNewswireAchieved Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Activity Report for Quarter Ended March 31, 2026 (Appendix 4C) NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited
- 6mo agoMESOMesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back PainGlobeNewswireNEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its pivotal Phase 3 clinical trial
- 7mo agoMESOMesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell ProductsGlobeNewswireNEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has acquired an exclusive
- 7mo agoMESOMesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTIONGlobeNewswireWorking with Parent Project Muscular Dystrophy and the Duchenne Registry on patient identification and trial awareness efforts ~15,000 children are living with DMD in the U.S. NEW YORK, April 10, 2026 (GLOBE
- 7mo agoMESOMesoblast R&D Day Features Significant Commercial Progress & Platform InnovationGlobeNewswireMesoblast outlines commercial strategy to double net revenues as Ryoncil® approaches US$100M net revenue milestone since launch last year Showcases transformative blockbuster products for inflammatory back pain
- 7mo agoMESOMesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular DystrophyGlobeNewswirePartnering with Parent Project Muscular Dystrophy to ensure timely access to the trial for eligible patients ~15,000 children are living with DMD in the U.S. NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Mesoblast
- 7mo agoMESORyoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March QuarterGlobeNewswireStrong growth in February/March following January seasonality Net revenue approaches US$100M since launch NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in
- 7mo agoMESOLGVNLCTXMNKDA Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.PR NewswireEquity-Insider.com — There is a key "master" protein in your body called α-Klotho. You've probably never heard of it. But the scientific community...
- 8mo agoFBLGFATEMESOLGVNCell Therapies Moving From Lab to Factory Floor, and the Stocks Behind ThemPR NewswireUSANewsGroup.com News Commentary — The global cell therapy market is projected to surpass $8.2 billion in 2026, driven by a wave of clinical...
- 8mo agoMESORyoncil® Profits Underpinning Substantial Growth PipelineGlobeNewswireNEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational
- 8mo agoMESOMesoblast Financial Results and Corporate Update WebcastGlobeNewswireNEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and
- 9mo agoMESOHigh Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHDGlobeNewswireNEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today provided data presented at the February 2026 Tandem
- 9mo agoMESORyoncil® Net Revenues Increase for the Quarter to US$30MGlobeNewswireNEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for
- 9mo agoMESOReal-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of TreatmentGlobeNewswireNEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on use of Ryoncil®
- 9mo agoMESOFDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product EfficacyGlobeNewswireNEW YORK, Jan. 18, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today provided feedback received from the U.S. Food &
- 10mo agoMESORyoncil® Sales Increase 60% in December Quarter to US$35.1MGlobeNewswireNEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced gross revenue of US$35.1 million on
- 10mo agoMESOMesoblast Announces Changes to Board of Directors' Leadership RolesGlobeNewswireNEW YORK, Jan. 01, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that as foreshadowed at the recent Annual
- 10mo agoMESOMesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit LineGlobeNewswireMesoblast has option to draw down up to US$125 million by June 30, 2026 New facility does not encumber any of Mesoblast's material assets or intellectual property NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) --
- 11mo agoPROKMESOLCTXBeyond Insulin Pumps: Cell Therapies Unlock a $403B Cure EconomyPR NewswireThe cell therapy manufacturing sector reached a pivotal inflection point in late 2025, with contract development and manufacturing organizations...
- 11mo agoMESOIndependent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHDGlobeNewswireNEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that an independent peer-reviewed
- 11mo agoMESOMesoblast Participation at Piper Sandler ConferenceGlobeNewswireNEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its participation at the Piper Sandler
- 11mo agoMESOMesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® RevenueGlobeNewswireNEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today provided a trading update, together with a
- 11mo agoMESOMesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to SteroidsGlobeNewswireNEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that given the high rate of
- 11mo agoMESOJames M. O'Brien Appointed Chief Financial Officer at MesoblastGlobeNewswireNEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that in connection with the Company's
- 1y agoMESOMesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid CessationGlobeNewswireNEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the U.S. Food & Drug
- 1y agoMESORyoncil® Net Revenues Increase 69% in Second Quarter Post LaunchGlobeNewswireNEW YORK, Oct. 19, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for
- 1y agoMESORyoncil® Revenues Increase 66% in Second Quarter Post LaunchGlobeNewswireNEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced gross revenue of US$21.9 million on
- 1y agoMESORyoncil® Receives J-Code From Medicare & Medicaid Services (CMS) Facilitating Reimbursement and Broader Patient AccessGlobeNewswireNEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that a specific Healthcare Common
- 1y agoMESOMesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to TariffsGlobeNewswireNEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today reiterated that its allogeneic cell therapy
- 1y agoMESOSuccessful Commercial Launch of Ryoncil® Highlighted at Global Healthcare ConferencesGlobeNewswireNEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, announced that the successful commercial launch of
- 1y agoMESOMesoblast Enters Into Option To Issue US$50 Million Convertible NotesGlobeNewswireNEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has entered into convertible note
- 1y agoMESOMesoblast Limited (MESO) Q4 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoMESONBIBanner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil®GlobeNewswireNEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited ((ASX:MSB, NASDAQ:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational
- 1y agoMESOMesoblast Financial Results and Corporate Update WebcastGlobeNewswireNEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited ((ASX:MSB, NASDAQ:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and
- 1y agoMESOSuccessful Commercial Launch of Ryoncil®GlobeNewswireNEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced gross revenue from sales of Ryoncil®
- 1y agoMESOMesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart FailureGlobeNewswireNEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced alignment with the United States Food and Drug
- 1y agoMESOMesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHDGlobeNewswireNEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on continued momentum with United States
- 1y agoMESOFDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil®GlobeNewswireNEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Mesoblast (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received seven years of orphan-drug
- 1y agoMESOAppendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025GlobeNewswireNEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for